Target Gene/Pathway(薬物標的遺伝子/パスウェイリスト)
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z other
| No. | KEGG PATHWAY * On map, Yellow: Drug target, Red: Disease-related |
KEGG GENES * | KEGG DRUG * | DrugBank | 指定難病告示番号 * |
| 1 | Acute myeloid leukemia |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 2 | Adipocytokine signaling pathway |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 3 | Adrenergic signaling in cardiomyocytes |
2件: ADRB1, ADRB2 | D00483 | Propranolol | 5件: 6, 158, 167, 227, 278 |
| D08443 | |||||
| 4 | AMPK signaling pathway |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 5 | Apelin signaling pathway |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 6 | Autophagy - animal |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 7 | Autophagy - other |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 8 | Breast cancer |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 9 | Calcium signaling pathway |
3件: ADRB1, ADRB2, ADRB3 | D00483 | Propranolol | 5件: 6, 158, 167, 227, 278 |
| D08443 | |||||
| 10 | cAMP signaling pathway |
2件: ADRB1, ADRB2 | D00483 | Propranolol | 5件: 6, 158, 167, 227, 278 |
| D08443 | |||||
| 11 | Cellular senescence |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 12 | Central carbon metabolism in cancer |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 13 | cGMP-PKG signaling pathway |
3件: ADRB1, ADRB2, ADRB3 | D00483 | Propranolol | 5件: 6, 158, 167, 227, 278 |
| D08443 | |||||
| 1件: PDE5A | D02229 | Sildenafil | 16件: 6, 46, 50, 51, 85, 86, 96, 113, 210, 211, 212, 225, 226, 278, 294, 299 | ||
| D08514 | |||||
| 14 | Choline metabolism in cancer |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 15 | Colorectal cancer |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 16 | Dilated cardiomyopathy (DCM) |
1件: ADRB1 | D00483 | Propranolol | 5件: 6, 158, 167, 227, 278 |
| D08443 | |||||
| 17 | EGFR tyrosine kinase inhibitor resistance |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 18 | Endocrine resistance |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 19 | ErbB signaling pathway |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 20 | Gap junction |
1件: ADRB1 | D00483 | Propranolol | 5件: 6, 158, 167, 227, 278 |
| D08443 | |||||
| 21 | Gastric cancer |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 22 | Glioma |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 23 | Growth hormone synthesis, secretion and action |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 24 | Hepatocellular carcinoma |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 25 | Herpes simplex virus 1 infection |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 26 | HIF-1 signaling pathway |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 27 | Human cytomegalovirus infection |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 28 | Human immunodeficiency virus 1 infection |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 29 | Human papillomavirus infection |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 30 | Insulin resistance |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 31 | Insulin signaling pathway |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 32 | JAK-STAT signaling pathway |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 33 | Kaposi sarcoma-associated herpesvirus infection |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 34 | Longevity regulating pathway |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 35 | Longevity regulating pathway - multiple species |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 36 | Metabolic pathways |
1件: PDE5A | D02229 | Sildenafil | 16件: 6, 46, 50, 51, 85, 86, 96, 113, 210, 211, 212, 225, 226, 278, 294, 299 |
| D08514 | |||||
| 37 | MicroRNAs in cancer |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 38 | mTOR signaling pathway |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 39 | Neuroactive ligand-receptor interaction |
3件: ADRB1, ADRB2, ADRB3 | D00483 | Propranolol | 5件: 6, 158, 167, 227, 278 |
| D08443 | |||||
| 40 | Pancreatic cancer |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 41 | Pathways in cancer |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 42 | PD-L1 expression and PD-1 checkpoint pathway in cancer |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 43 | Phospholipase D signaling pathway |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 44 | PI3K-Akt signaling pathway |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 45 | Prostate cancer |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 46 | Proteoglycans in cancer |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 47 | Purine metabolism |
1件: PDE5A | D02229 | Sildenafil | 16件: 6, 46, 50, 51, 85, 86, 96, 113, 210, 211, 212, 225, 226, 278, 294, 299 |
| D08514 | |||||
| 48 | Regulation of lipolysis in adipocytes |
3件: ADRB1, ADRB2, ADRB3 | D00483 | Propranolol | 5件: 6, 158, 167, 227, 278 |
| D08443 | |||||
| 49 | Renin secretion |
3件: ADRB1, ADRB2, ADRB3 | D00483 | Propranolol | 5件: 6, 158, 167, 227, 278 |
| D08443 | |||||
| 50 | Salivary secretion |
3件: ADRB1, ADRB2, ADRB3 | D00483 | Propranolol | 5件: 6, 158, 167, 227, 278 |
| D08443 | |||||
| 51 | Shigellosis |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 52 | Th17 cell differentiation |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 53 | Thermogenesis |
1件: ADRB3 | D00483 | Propranolol | 5件: 6, 158, 167, 227, 278 |
| D08443 | |||||
| 1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 | ||
| 54 | Thyroid hormone signaling pathway |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 55 | Type II diabetes mellitus |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |